The estrogen receptor alpha (ERα) is highly expressed in both endometrial and breast cancers, and represents the most prevalent therapeutic target in breast cancer. However, anti-estrogen therapy has not been shown to be effective in endometrial cancer. Recently it has been shown that hormone-binding domain alterations of ERα in breast cancer contribute to acquired resistance to anti-estrogen therapy. In analyses of genomic data from The Cancer Genome Atlas (TCGA), we observe that endometrial carcinomas manifest recurrent ESR1 gene amplifications that truncate the hormone-binding domain encoding region of ESR1 and are associated with reduced mRNA expression of exons encoding the hormone-binding domain. These findings support a role for hormone-binding alterations of ERα in primary endometrial cancer, with potentially important therapeutic implications.
Results
Across a cancer study subset of 29 primary endometrial carcinomas that had gone on to metastasize, we characterized the copy-number changes by GeneChips and validated amplifications of ESR1 in these cancers by fluorescence in-situ hybridization (FISH). The Pearson correlation of ESR1 GeneChip copy numbers with FISH determined absolute average ESR1 copy numbers per nucleus and average ESR1 to centromere 6 (CEN6) ratios were r = 0.743 (p < 0.001) and r = 0.774 (p < 0.001) respectively (Appendix A, Fig. 1 , Supplementary Figures S1 and S2, Supplementary Optical Dataset S1).
Four of these tumors exhibited focal ESR1 amplification determined by GeneChips, of which two amplifications showed 3′ truncations of ESR1 (Δ exon 6-8 or 7-8) that would remove the hormone-binding domain Figure  2 ). Regarding FISH signals of ESR1 (green) and centromere 6 (orange) within a tumor nucleus (blue) are shown on the right. FISH and regarding GeneChip copy-number data of 28 metastatic endometrial carcinoma are summarized in Appendix A. FISH analyses of these tumors are documented in Supplementary Optical Dataset S1.
Scientific RepoRts | 6:25521 | DOI: 10.1038/srep25521 (Appendix A, Fig. 1 ). We therefore explored the prevalence of ESR1-truncating amplifications across uterine corpus endometrial carcinoma within The Cancer Genome Atlas (TCGA) 33 .
Hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers.
In the TCGA data subset of 539 endometrial carcinomas analyzed, we identified 88 (16.3%) cases with amplifications encompassing or overlapping ESR1. 46.6% of these were histologically defined serous and 75.0% of the tumors with ESR1 amplification were clustered within the serous like copy-number high molecular subtype according to TCGA 34 . The ESR1 amplifications were focal (less than half a chromosome arm in length) in 36 cases (6.7%) of tumors, and had a significantly higher rate of amplification than the genome-wide average (q = 5.75 × 10 −4 ). Mapping of the overlap between amplifications across tumors identified ESR1 only as the most likely gene target (see methods).
These amplifications appeared to truncate the hormone-binding domain encoding region in seven cases (1.3% of the entire dataset; and 19.4% of cases with focal ESR1 amplification) and to retain exons 1-4 or 1-3, encoding the n-terminal ESR1 transactivation domain (AF1) and DNA-binding domains. Another case without ESR1 amplification exhibited a heterozygous deletion of exons encoding the hormone-binding domain (Fig. 2) , for a total apparent ESR1 truncation rate of 1.5% over all tumors. In one additional TCGA case, we detected a hormone-binding domain (exons 4-8) truncating ESR1-SYNE1 mRNA fusion (Appendix B). Eight of these nine tumors were molecularly classified as being in the serous like copy-number high subgroup (4.3% of this subgroup) 35 .
Association of ESR1 exon copy numbers with mRNA expression. The ESR1 truncation events are associated with decreased mRNA expression of the truncated exons encoding the hormone-binding domain (exons 5-8) compared to the transactivation and DNA-binding domains (exons 1-4) (p < 0.001) ( Fig. 2 and Appendix C). We compared the normalized ESR1 expression values estimated from RNA-Seq data for the eight tumors exhibiting amplified, truncated ESR1 to those from eight tumors selected on the basis of exhibiting similarly focal ESR1 amplifications that lack intragenic breakpoints. The average ratio between expression levels of exons 1-4 and 5-8 is 2.1-fold higher among truncated tumors relative to these controls (p = 0.003). We also confirmed this relation after replacing the eight ESR1-amplified controls with all 545 tumors profiled by TCGA. In this comparison, the ratio of expression levels between exons 1-4 and 5-8 is 2.2-fold higher in ESR1-truncated tumors (p < 0.001).
In contrast, TCGA breast cancers exhibit ESR1 truncations on DNA-level less than half as often (7 of 1080; 0.65%) as observed in endometrial cancer and had increased expression of exons 1-2, but not of the full DNA-binding domain (Appendix D). These data suggest that the amplified truncations and associated mRNA profiles we describe in endometrial cancer are not frequent in breast cancer.
Discussion
The gene truncations we report in endometrial carcinoma disrupt the hormone-binding domain encoding sequence of ESR1. Similarly, mRNA splice variants lacking one or more of exons 5-8, encoding the hormone-binding domain, have been described in normal [35] [36] [37] [38] and malignant 22, 23, [35] [36] [37] 39 breast as well as in normal 22, [40] [41] [42] [43] [44] [45] and malignant 42-46 endometrial tissue. Point mutations of the ligand binding domain encoding sequence of ESR1 have also been described to occur in both breast and endometrial cancers [25] [26] [27] 30, 47, 48 .
Both splice variants and point mutations involving the ESR1 hormone-binding domain have been associated with hormone-independent ERα activity. The point mutations found in both breast and endometrial cancers have been shown to enable ligand-binding independent transcriptional activity 26, 30, [48] [49] [50] and have been related to acquired resistance to anti-estrogen therapy in breast cancer [26] [27] [28] . Excisions of exons 5 and 7 by alternative splicing have also been shown to constitutively activate ERα 22, 23, 30 and have been associated with hormone independent growth in both breast and endometrial cancer [22] [23] [24] 31 . These findings raise the hypothesis that the ESR1 truncations we report may also generate hormone-independent ERα activity.
In breast cancer, point mutations in the ligand-binding domain occur in 20-50% of tumors that have acquired resistance to anti-estrogen therapy 26, 27 but only in 0.2% of primary cancers 51 . In endometrial cancer, however, point mutations and in-frame deletions altering the ligand binding domain occur in 2.8% of primary endometrial cancers 26, 51 . Similarly the recurrent ESR1 truncations we report appear to be much more frequent in primary endometrial carcinoma than in primary breast cancers.
Anti-estrogen therapy with estrogen antagonists or aromatase inhibitors is standard first-line treatment for ERα-positive breast cancers, but has been associated with only a low rate (~10%) of overall response among endometrial cancers 13, [16] [17] [18] and is not a standard treatment for endometrial cancer 3, 4 . In some cases, anti-estrogens such as Tamoxifen can even induce proliferation effect on endometrial cancer cells 52, 53 and normal endometrial tissue 54 and increase the risk of endometrial carcinogenesis [19] [20] [21] . Splice variants of ESR1 that alter the hormone-binding domain have been associated with ERα activation by Tamoxifen in endometrial cancer cells 24 . The effect of estrogen antagonists on ERα encoded by the truncated forms of ESR1 that we have detected should also be tested, and all alterations of the ESR1 ligand-binding domain should be evaluated as potential biomarkers of anti-estrogen therapy resistance. Conversely, the absence of such alterations should be evaluated as a biomarker of anti-estrogen sensitivity, potentially opening up a new therapeutic option for a subset of patients with endometrial cancer.
Methods
GeneChip analysis. For our study subset of 29 primary endometrial tumors, gene copy-number data were determined by Affymetrix SNP 6.0 microarray analysis as described earlier 55 . GeneChip probe intensities are normalized across samples and circular binary segmentation is performed. Areas harboring germline CNVs are removed from the final segmented copy-number output. The range of birdseed call rates in this cohort was 92.6-99.3% with an average call rate of 97.1%. For TCGA copy-number data, level 3 segmented log2 copy-number data were used in analysis. For both datasets, log2 copy-number values are calculated as ratios relative to the genome wide average according to standard procedures [56] [57] [58] [59] . These gene copy-number data were visualized using the IGV viewer software 60 . Linear gene level copy-number data were derived by GISTIC 55, 59 . All TCGA DNA copy-number data (2015-06-01 stddata 2015-04-02 regular peel-off) can be accessed through the TCGA Copy Number Portal 57 .
RNA-Seq analysis. Reads per kilobase per million (RPKM) 61 RNA exon expression quantification values
were normalized and RPKM 0 was assigned 0.1 (Appendices C+D). Exons were compared using inverted log2 of normalized values. A two tailed Mann-Whitney-U-Test was applied to test for statistical significance of differences. P-values < 0.05 were considered statistically significant. Paired-end RNA-seq fusion transcript analysis of TCGA RNA-sequencing data from 295 tumors to detect mRNA fusions was performed using SnowShoes-FTD as described earlier [62] [63] [64] . Parameters used to define a fusion transcript of high confidence were at least two unique fusion junction spanning split reads within the dataset and at least five encompassing reads 65 . RNA-Seq data were taken from the TCGA database http://cancergenome.nih.gov Scientific RepoRts | 6:25521 | DOI: 10.1038/srep25521 FISH analysis. FISH was performed without RNase treatment as described earlier 66 . Pearson correlation coefficients and regarding p-values (two sided t-test) were generated using SPSS (Statistical Package of Social Science) version 20.0.0 applying standard bootstrapping. P-values < 0.05 were considered statistically significant.
Tumor samples and DNA extraction. This study has been approved by the Norwegian Data Inspectorate (961478-2), the Norwegian Social Science Data Services (15501) and the local Institutional Review Board (REKIII nr. 052.01) and the BROAD institute, MA, USA and methods were carried out in accordance with these approved guidelines. The 29 metastatic high grade primary tumor samples were obtained with documented informed consent in a patient based setting (Sept 2002-Sept 2012) from the Department of Obstetrics and Gynaecology, Section of Gynaecological Cancer, Haukeland University Hospital, Bergen, Norway. Biopsies were snap frozen in nitrogen and stored at minus 80 °C until DNA extraction. Tumor purity was assessed based on histology sections obtained by microtome prior to DNA extraction. DNA extraction was performed using samples with estimated tumor purity ≥ 50% as previously described 7 .
